The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Performance was driven by strong execution across the specialty pharmaceutical platform, particularly within health systems and physician practices.

The MSO platform, including OneOncology and Retina Consultants of America (RCA), performed ahead of expectations, benefiting from the ability to attract physicians to the network.

Management attributed double-digit organic operating income growth in the U.S. to underlying specialty strength, even when excluding the OneOncology acquisition and a prior customer loss.

Digital transformation efforts, including AI-driven demand forecasting, are being utilized to improve product availability and reduce manual operational processes.

The value proposition remains resilient despite manufacturer list price reductions, which acted as a $2.4 billion headwind to revenue but did not derail profit growth.

International growth was supported by European distribution and specialty logistics, specifically benefiting from the timing of manufacturer price adjustments in developing markets.

Full-year adjusted EPS guidance was raised to $17.75–$17.95, reflecting confidence in continued execution and the strength of the specialty portfolio.

U.S. Healthcare Solutions revenue is expected to land in the lower half of the 4% to 6% growth range due to current market expectations and pricing dynamics.

Management expressed confidence in long-term guidance for fiscal 2027, despite a projected $0.35 EPS headwind from the pending MWI Animal Health merger.

The strategy for MSO growth remains focused on accretive tuck-in acquisitions within the oncology and retina spaces rather than expanding into new disease states.

Biosimilars are viewed as a long-term profit driver, particularly in the Part B buy-and-bill space where Cencora provides extensive wraparound services.

Completed $1 billion in opportunistic share repurchases during the quarter, contributing to the 12% EPS growth.

The MWI Animal Health business is currently accounted for as 'held for sale' pending a merger with Covetrus, which provided a temporary accounting benefit to the Other segment.

Management is monitoring proposed 340B and IRA Part B policy changes, asserting that reimbursement mechanisms are being designed to avoid negatively impacting community physician economics.

Debt repayment remains a priority, with the company fully paying off an $800 million term loan related to recent acquisition financing.

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.

Management noted that Q4 is expected to show the strongest organic growth of the year as they fully lap the loss of a large oncology customer.

Confirmed that while specific 2027 guidance is pending, the company remains comfortable with its long-term growth algorithm and market positioning.

Management clarified that Part B biosimilars offer a larger profit opportunity due to the complex distribution, GPO, and MSO services required by physicians.

Part D biosimilars are still viewed as positive but provide less incremental profit because they require fewer wraparound services and can lead to revenue pressure if customers in-source.

The MSO strategy is in three phases: integration, sharing capabilities (like clinical trials), and developing new services like advanced analytics.

RCA is considered to be in the 'later innings' of its clinical trial platform build-out, while OneOncology is in the 'earlier innings' with significant room for expansion.

Management emphasized that while new competitors are entering the 3PL space, Cencora differentiates by focusing exclusively on high-end pharmaceutical-centric services.

World Courier is seeing momentum as the clinical trial market stabilizes following a more challenging fiscal 2025.